Related Experiment Video
Updated: Oct 13, 2026
Pseudomonas aeruginosa Induced Lung Injury Model
Published on: October 29, 2014
Recent experience with Pseudomonas aeruginosa immune globulin for the treatment of experimental pneumonia
1Department of Medicine, University of California, San Francisco.
A guinea-pig model of experimental Pseudomonas aeruginosa pneumonia was used to determine what factors affect the efficacy of passive immune therapy with a hyperimmune P. aeruginosa globulin (PA-IGIV). Animals treated 2 h after infection with a single iv infusion of PA-IGIV, 500 mg kg-1, demonstrated 33% survival. Lower dosages were less effective and there were no survivors among albumin-treated controls. Treatment with PA-IGIV was effective if given 2 or 8 h after infection but not if delayed until 24 h after infection. Animals rendered neutropenic with cyclophosphamide did not survive if treated with PA-IGIV alone. However, when PA-IGIV was added to tobramycin treatment, a significant increase in survival occurred (86%) as compared with that observed with tobramycin alone (43%) (P less than 0.05). We conclude that PA-IGIV may offer a useful therapeutic option in management of P. aeruginosa pneumonia.
A guinea-pig model of experimental Pseudomonas aeruginosa pneumonia was used to determine what factors affect the efficacy of passive immune therapy with a hyperimmune P. aeruginosa globulin (PA-IGIV). Animals treated 2 h after infection with a single iv infusion of PA-IGIV, 500 mg kg-1, demonstrated 33% survival. Lower dosages were less effective and there were no survivors among albumin-treated controls. Treatment with PA-IGIV was effective if given 2 or 8 h after infection but not if delayed until 24 h after infection. Animals rendered neutropenic with cyclophosphamide did not survive if treated with PA-IGIV alone. However, when PA-IGIV was added to tobramycin treatment, a significant increase in survival occurred (86%) as compared with that observed with tobramycin alone (43%) (P less than 0.05). We conclude that PA-IGIV may offer a useful therapeutic option in management of P. aeruginosa pneumonia.
More Related Videos
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
05:40Establishment of A Mouse Sepsis-Induced Immunosuppression Model By Intranasal Instillation of Bacteria
Published on: June 12, 2026
